Compare Linde PLC (LIN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Regeneron Pharmaceuticals Inc — how do they compare? Linde PLC trades at $483.98 (market cap $222.05B), while Regeneron Pharmaceuticals Inc trades at $746.12 (market cap $76.14B). The key difference: Linde PLC is far larger — about 2.9× Regeneron Pharmaceuticals Inc's market cap, and Linde PLC pays the higher dividend (1.33%). Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 88 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| LIN | REGN | |
|---|---|---|
Market Cap | $222.05B | $76.14B |
Volume | 2,116,440 | 500,239 |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $852.03 |
52-Week Low | $389.38 | $557.73 |
Typical Hold Time | 88 Days | 107 Days |
Enterprise Value | $245.17B | $70.85B |
Dividend Yield | 1.33% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIN trades at $483.98, down 1.22% on the day, with a bullish technical signal from moving averages and strong support near $482. The company reported record Q2 2026 EPS of $4.50, beating estimates, and maintains robust profitability with a 20.43% net income margin. Revenue growth is steady, projected at $35.4B for 2026, while valuation multiples like the 31.08 P/E reflect premium pricing. Analyst sentiment is overwhelmingly positive, with 89.66% buy ratings and a $557.10 consensus price target, citing LIN's role in AI chip supply chains.
The outlook for LIN is favorable, driven by earnings beats, a record $8.1B project backlog, and strategic positioning in high-growth sectors like electronics. Key risks include elevated valuation requiring sustained growth, rising debt-to-asset ratios, and margin pressures from increased capital expenditure. Investors should weigh the company's strong execution against potential sector-wide competition and macroeconomic headwinds affecting industrial demand.
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
